Cerus Corporation Announces Five-Year FDA Contract for the Development of Next Generation Pathogen Reduction Technology to Treat Whole Blood
Cerus Corporation (CERS)
Last cerus corporation earnings: 2/20 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cerus.com/investors/investor-overview/default.aspx
Company Research
Source: Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR) treatment of whole blood to reduce the risk of transfusion-transmitted infections. The contract value totals $11.1 million. This research is consistent with the FDA’s strategy for developing proactive, foundational interventions to ensure blood safety and availability1.Given the possible benefits of whole blood transfusion2, pathogen reduced whole blood has the potential to fundamentally reshape the support of patients with massive hemorrhage.“We appreciate the FDA’s support of Cerus’ research program for whole blood PR technology,” said Dr. Nina Mufti, program leader for both the Whole Blood and Red Blood Cell programs at Cerus. “A whole blood PR solution would complement Cerus’ portfolio of marketed pathogen reduction products for
Show less
Read more
Impact Snapshot
Event Time:
CERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERS alerts
High impacting Cerus Corporation news events
Weekly update
A roundup of the hottest topics
CERS
News
- Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024Business Wire
- Cerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64% [Yahoo! Finance]Yahoo! Finance
- Cerus gains as Craig Hallum launches at Buy on return to growth [Seeking Alpha]Seeking Alpha
- Cerus Co. (NASDAQ: CERS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life [Yahoo! Finance]Yahoo! Finance
CERS
Earnings
- 3/5/24 - In-Line
CERS
Sec Filings
- 3/19/24 - Form 8-K
- 3/14/24 - Form 4
- 3/14/24 - Form 4
- CERS's page on the SEC website